A peptide antagonist of the TLR4-MD2 interaction. - Wikidata - wikimedia - TriplyDB

A peptide antagonist of the TLR4-MD2 interaction.

A peptide antagonist of the TLR4-MD2 interaction.

http://www.wikidata.org/entity/Q34315638

about

Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia Computational Approaches to Toll-Like Receptor 4 Modulation Targeting Toll-like receptors with small molecule agents Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions?Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.Toll-like receptor 4 in CNS pathologies Break CDK2/Cyclin E1 interface allosterically with small peptides.Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor.Targeting protein-protein interfaces using macrocyclic peptides.Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation Morphine activates neuroinflammation in a manner parallel to endotoxin An MD2 hot-spot-mimicking peptide that suppresses TLR4-mediated inflammatory response in vitro and in vivo Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.Lipidated cyclic γ-AApeptides display both antimicrobial and anti-inflammatory activity.M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway.The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease.Selection, Preparation, and Evaluation of Small- Molecule Inhibitors of Toll-Like Receptor 4.Interfering with the high-affinity interaction between wheat amylase trypsin inhibitor CM3 and toll-like receptor 4: in silico and biosensor-based studies.Contributions and Future Directions for Structural Biology in the Study of Allergens.TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.Pyrimidine Triazole Thioether Derivatives as Toll-Like Receptor 5 (TLR5)/Flagellin Complex Inhibitors.

P2860

Q24612607-3052F40A-906A-4F24-858A-2BB357CC85B3 Q24650739-29DED2D4-2827-4B23-AA7A-405F6CCCEA00 Q26740008-60A80CB0-5DE8-4228-9547-C7A0F8C5CA93 Q26992220-160A923C-1070-427A-89B0-5F8F46663EB9 Q30496929-E9B436B0-D5A4-4712-B846-26AC8D9F0F94 Q33693637-E652F38D-44D9-4729-A34C-526D9D663F3E Q34018705-E35A9DF2-E1E1-4CB3-924E-36968FC2CBD4 Q34301581-56F2310A-F27F-4D6A-AD85-F6538074A539 Q34493434-C6C17493-6181-40EE-BF8F-EEAEC53847BF Q35112532-A57F9DB5-CFA5-449D-A0C6-EDDA7ED27D14 Q35558196-AE75DB11-388E-4C9F-A1EB-7EDDDA6A5C5A Q35681383-B3D707B0-479E-4A41-A3D3-26EC7C4E15F4 Q35924760-686BAF2E-CF0F-4EBE-8E11-138C8C0A0FC9 Q36030855-9E292F62-00BC-49AF-AF24-F6CB678B5147 Q37506796-0A04B38B-379C-40DF-AEBE-080D9AB17E7D Q39076004-96982D1F-66D2-4181-9E17-88CA0B61C758 Q39108821-E82EE51B-EC88-42A5-9908-BCC573D29394 Q41599612-57B3BA86-3CE4-472C-A9D7-6E75EA192B43 Q42124217-4707EA69-EE5D-4346-9AD9-1E5B4DC4D229 Q42377237-D61F72CD-2101-4202-B8E2-7CE6434C40AB Q47676049-8C4131D8-E60B-4FEC-BBC9-23FF66BE82A6 Q48641496-7857D974-6C6E-4DC3-8387-32BFDBB2ABD4 Q53393586-8C40861A-A65A-4BB9-8927-B4E8ABA2F109

P2860

A peptide antagonist of the TLR4-MD2 interaction.

http://www.wikidata.org/entity/Q34315638

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A peptide antagonist of the TLR4-MD2 interaction.

@ast

A peptide antagonist of the TLR4-MD2 interaction.

@en

A peptide antagonist of the TLR4-MD2 interaction.

@nl

type

label

A peptide antagonist of the TLR4-MD2 interaction.

@ast

A peptide antagonist of the TLR4-MD2 interaction.

@en

A peptide antagonist of the TLR4-MD2 interaction.

@nl

prefLabel

A peptide antagonist of the TLR4-MD2 interaction.

@ast

A peptide antagonist of the TLR4-MD2 interaction.

@en

A peptide antagonist of the TLR4-MD2 interaction.

@nl

P1433

Q34315638-1D1EBDC1-4422-403B-AFD5-374A2B9BCF99

P1476

Q34315638-D355DB03-D945-4405-BD14-63BAEB97B5EC

P2093

Q34315638-38BB8B72-7300-4B54-A164-E14FD66C365F

Q34315638-3D714381-9F6F-4E5E-BCDF-3C520257B816

Q34315638-40844D47-8B28-4E2C-B144-D1E9A07F0C60

Q34315638-4E795AE3-A189-4B25-B42D-355232FEEB67

Q34315638-848A93A8-54F4-47B6-8A34-53C4AAEECDA5

Q34315638-D6134DAF-4C34-4DCC-A72C-90E114995F69

Q34315638-DADF8ABD-268E-4260-815B-42E4C88CA1B8

Q34315638-DF220324-D319-42BA-8107-677D3DA9332A

Q34315638-F83CA019-FAD6-4C33-8A64-8C66997A4C14

Q34315638-FF78E9DE-6628-48B8-B3D1-13765D79C9BB

P2860

Q34315638-137A7D4F-5DFD-46BA-9B18-4422E00EAB67

Q34315638-1776FCB0-7754-4BF2-B423-76C3AFC693BB

Q34315638-1D58A7A9-0A1C-490E-9F57-343601855E68

Q34315638-25E8B7DA-CD21-4BDC-8FF4-E3427592DD58

Q34315638-261EFEEA-013F-464D-8100-6E680040E4CC

Q34315638-2CD6283E-7B21-47CA-A7F0-4CE23C86C201

Q34315638-2D212F76-8B33-4A96-A1CB-E4D786D3B033

Q34315638-3883A635-A027-46C8-86B5-DABDBCA8633A

Q34315638-52AF7CAD-9B6F-41D7-8970-490C4B286BF2

Q34315638-705E0A3F-4A67-46AB-8AB0-47AA9B92A946

P304

Q34315638-0C3828DB-79BD-4ACC-9514-0221A83A453D

P31

Q34315638-4D5B6C61-4F4D-4C26-A007-ABB45F1DF0EC

P356

Q34315638-05444DEC-61CD-4865-A962-0F74123FAB91

P433

Q34315638-8C26010F-3CCA-40CE-8F14-973AFB800D57

P478

Q34315638-D118FBE7-0651-459A-B469-5F6F16D4F25F

P50

Q34315638-28C7EE4C-481E-45BB-BC70-AC63B9635EC7

Q34315638-36AB3A09-1FC8-476E-B796-47B2797B4E95

P577

Q34315638-ECA4142E-4054-4DDA-92A2-3FF690BC4545

P5875

Q34315638-8604129B-245F-4607-925C-1C8643856AE1

P698

Q34315638-EAB16BEC-7B09-45AE-87EC-E004716E0D2F

P921

Q34315638-249891A6-6230-4EB1-B3A2-E39C39E80F2D

P932

Q34315638-8B27D424-1F54-4CA9-900E-427C4539F061

P356

P1433

P1476

A peptide antagonist of the TLR4-MD2 interaction.

@en

P2093

Alexander J Martinko

http://www.w3.org/2001/XMLSchema#string

Deanne W Sammond

http://www.w3.org/2001/XMLSchema#string

Gui-in Lee

http://www.w3.org/2001/XMLSchema#string

Hang Yin

http://www.w3.org/2001/XMLSchema#string

Jacqueline A Harrison

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Kearney

http://www.w3.org/2001/XMLSchema#string

Madison M Buchanan

http://www.w3.org/2001/XMLSchema#string

Mitesh Shridhar

http://www.w3.org/2001/XMLSchema#string

Page W Sholar

http://www.w3.org/2001/XMLSchema#string

Peter F Slivka

http://www.w3.org/2001/XMLSchema#string

P2860

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran

TLR signaling pathways

High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design

Native protein sequences are close to optimal for their structures

Pathogen recognition and innate immunity

Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction

The danger model: a renewed sense of self

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)

Protein structure prediction using Rosetta

P304

645-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CBIC.200800769

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Linda R. Watkins

Mark R. Hutchinson

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23966749

http://www.w3.org/2001/XMLSchema#string

P698

19184989

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

2982775

http://www.w3.org/2001/XMLSchema#string